<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570608</url>
  </required_header>
  <id_info>
    <org_study_id>EK 06-233-0107</org_study_id>
    <secondary_id>2006-006760-28</secondary_id>
    <nct_id>NCT01570608</nct_id>
  </id_info>
  <brief_title>Lucentis KAV Study</brief_title>
  <official_title>Comparison of Ranibizumab (Lucentis) Monotherapy Versus Combination of Ranibizumab (Lucentis) With Photodynamic Therapy (Verteporfin) in Patients With Subfoveal Choroidal Neovascularisation Due to Age-Related Macular Degeneration - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ranibizumab has been proven to be effective in large multicentre studies. However, the&#xD;
      injections have to be repeated monthly. A combined therapy with the established photodynamic&#xD;
      therapy might even be more effective, less intravitreal injections might be necessary due to&#xD;
      a synergistic effect.&#xD;
&#xD;
      The study will be conducted to explore whether intravitreal ranibizumab in monotherapy or in&#xD;
      combination with verteporfin photodynamic therapy under a new time regime is an effective,&#xD;
      safe and convenient treatment for patients with subfoveal Choroidal Neovascularisation (CNV)&#xD;
      secondary to Age-Related Macular Degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of injections</measure>
    <time_frame>baseline-month 12</time_frame>
    <description>Comparision of the number of required retreatments between the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of AE, SAE</measure>
    <time_frame>12 months</time_frame>
    <description>number of AE and SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central retinal thickness</measure>
    <time_frame>baseline-month 12</time_frame>
    <description>central retinal thickness measured by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distance acuity</measure>
    <time_frame>baseline-month 12</time_frame>
    <description>change of disance acuity measured by ETDRS letter scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>monotherapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving 3 initial Ranibizumab injections, thereafter as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combined treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>intravitreal injection 3 monthly injections thereafter as needed</description>
    <arm_group_label>combined treatment arm</arm_group_label>
    <arm_group_label>monotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin</intervention_name>
    <description>Verteporfin photodynamic therapy standard fluence</description>
    <arm_group_label>combined treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BCVA letter score in the study eye between 73-24 (approximately 20/40 to 20/320) using&#xD;
             an ETDRS chart measured at 4 meters or Snellen equivalent&#xD;
&#xD;
          -  CNV lesion of any type in the study eye which meets all the following characteristics&#xD;
             as determined by fluorescein angiography:&#xD;
&#xD;
               -  Evidence that CNV extends under the geometric center of the foveal avascular&#xD;
                  zone.&#xD;
&#xD;
               -  The area of the CNV must occupy at least 50% of the total lesion.&#xD;
&#xD;
               -  The lesion must be ≤ 5400 microns in greatest linear dimension (GLD)&#xD;
&#xD;
          -  For occult with no classic CNV, additionally recent disease progression as assessed by&#xD;
             the Investigator is required defined as having at least one of the following criteria:&#xD;
&#xD;
               -  Blood associated with the lesion at baseline&#xD;
&#xD;
               -  Loss of VA in the previous 3 months defined as either ≥ 5 letters (ETDRS&#xD;
                  equivalent) as determined by protocol refraction and protocol measurements, or 2&#xD;
                  or more lines using a Snellen or equivalent chart by standard examinations. ≥ 10%&#xD;
                  increase in the greatest diameter of the lesion in the previous 3 months as&#xD;
                  assessed by fluorescein angiography&#xD;
&#xD;
          -  Willing to return for scheduled visits for a 12 month period&#xD;
&#xD;
          -  Only one eye will be assessed in the study. If both eyes are eligible, the one with&#xD;
             the worse visual acuity will be selected for treatment and study unless, based on&#xD;
             medical reasons, the investigator deems the other eye the more appropriate candidate&#xD;
             for treatment and study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have a BCVA of &lt; 33 letters (approximately 20/200) in both eyes&#xD;
&#xD;
          -  Prior treatment in the study eye with verteporfin, external-beam radiation therapy,&#xD;
             vitrectomy, submacular surgery, other surgical intervention for AMD, or transpupillary&#xD;
             thermotherapy&#xD;
&#xD;
          -  Previous or current intravitreal drug delivery (e.g., intravitreal corticosteroid&#xD;
             injection or device implantation) in the study eye&#xD;
&#xD;
          -  Focal laser photocoagulation (juxta-, extra- or subfoveal) in the study eye&#xD;
&#xD;
          -  Concomitant use of chronic NSAIDs or steroids (by any route) for the duration of study&#xD;
             participation (chronic use is defined as multiple doses taken daily for three or more&#xD;
             consecutive days at any time during the study). Note that ASA (aspirin) taken as &quot;low&#xD;
             dose&quot; up to 100 mg qd for prophylaxis of MI and/or stroke is permitted during study&#xD;
&#xD;
          -  Current use or of likely need for systemic medications known to be toxic to the lens,&#xD;
             retina or optic nerve, including Deferoxamine, Chloroquine/ hydroxychloroquine&#xD;
             (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol is excluded&#xD;
&#xD;
          -  History of glaucoma filtration surgery, corneal transplant surgery or extracapsular&#xD;
             extraction of cataract with phacoemulsification within six months preceding Day One,&#xD;
             or a history of post-operative complications within the last 12 months preceding Day&#xD;
             One in the study eye (uveitis, cyclitis etc.)&#xD;
&#xD;
          -  History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥&#xD;
             25 mmHg despite treatment with topical anti-glaucomatous mediation).&#xD;
&#xD;
          -  Aphakia or absence of the posterior capsule in the study eye&#xD;
&#xD;
          -  Previous violation of the posterior capsule in the study eye is also excluded unless&#xD;
             it occurred as a result of YAG posterior capsulotomy in association with prior,&#xD;
             posterior chamber intraocular lens implantation&#xD;
&#xD;
          -  Spherical equivalent of the refractive error in the study eye demonstrating more than&#xD;
             -8 diopters of myopia&#xD;
&#xD;
          -  Presence of a retinal pigment epithelial tear involving the macula in the study eye&#xD;
&#xD;
          -  Angioid streaks or precursors of CNV in either eye due to other causes, such as ocular&#xD;
             histoplasmosis, trauma, or pathologic myopia&#xD;
&#xD;
          -  Active intraocular inflammation (grade trace or above) in the study eye&#xD;
&#xD;
          -  Any active infection involving an eyeball adnexa&#xD;
&#xD;
          -  Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole&#xD;
             (Stage 3 or 4) in the study eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilse Krebs, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ludwig Boltzmann Institute for retinology and biomicroscopic Lasersurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of OPhthalmology Medical center east</name>
      <address>
        <city>Vienna</city>
        <zip>A1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Rudolf foundation Clinic</name>
      <address>
        <city>Vienna</city>
        <zip>A1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Hospital Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>A1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 1, 2012</study_first_submitted>
  <study_first_submitted_qc>April 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ranibizumab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Verteporfin</keyword>
  <keyword>age-related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

